A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson’s disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Sanofi has finally had is type 2 diabetes drug, lixisenatide, approved in the US, creating further competition against Novo Nordisk’s market leading Victoza. The French pharma withdrew its US ...

Lixisenatide is under clinical development by Sanofi and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...

In this in-depth article, we delve deeper into the potential advantages of incorporating Lixisenatide, an innovative medication for diabetes management, into self-funded health plans. Employers aiming ...